| Popis: |
Dominick L Opitz,1 Jennifer S Harthan,1 Stephanie R Fromstein,1 Scott G Hauswirth2 1Department of Clinical Education, Illinois College of Optometry, Chicago, IL, 2Minnesota Eye Consultants, Minneapolis, MN, USA Abstract: Meibomian gland dysfunction (MGD) is commonly encountered among eye care professionals. Our understanding of the pathophysiology for the development of MGD has greatly expanded in recent years, which helped increase awareness of the disease. Despite increased awareness, it is essential for eye care professionals to make a conscious effort to properly examine the meibomian glands through gland expression even for asymptomatic patients. At minimum, early management should include patient education and supportive therapy such as warm compresses, lid hygiene, and gland expression. As patients become more symptomatic and as the ocular surface becomes more affected, employing additional therapeutic management is recommended and may include oral omega-3 essential fatty acids, topical azithromycin, oral tetracycline, and topical anti-inflammatories to improve clinical signs and patient comfort. In addition to treatment of MGD, clinicians should be mindful of the comorbid conditions of MGD and simultaneously manage them in conjunction of MGD treatment. Keywords: meibomian gland dysfunction, dry eye, blepharitis, ocular surface disease |
